
CLAIMS

1. A compound of formula I:




I

wherein:

R is selected from H and (C_1-C_{20})hydrocarbyl.

2. A compound according to claim 1 of formula II:



II.

3. A compound according to claim 2 wherein R is selected from H and aliphatic (C_1-C_{20})hydrocarbyl optionally substituted with one or two phenyl groups with the proviso that R contains twenty carbons or less.

4. A compound according to claim 2 wherein R is H or C_nH_m, and wherein:

n is 1 and m is 3;

n is 2 and m is 5;

n is 3 and m is 3, 5, or 7;

n is 4 and m is 5, 7, or 9;

n is 5 and m is 7, 9, or 11;

n is 6 and m is 5, 7, 9, 11, or 13.

n is 7 and m is 7, 9, 11, 13, or 15;

n is 8 and m is 5, 7, 9, 11, 13, 15, or 17;

n is 9 and m is 7, 9, 11, 13, 15, 17, or 19;

n is 10 and m is 7, 9, 11, 13, 15, 17, 19, or 21;

n is 11 and m is 9, 11, 13, 15, 17, 19, 21, or 23;

n is 12 and m is 7, 9, 11, 13, 15, 17, 19, 21, 23, or 25;

n is 13 and m is 9, 11, 13, 15, 17, 19, 21, 23, 25, or 27;

n is 14 and m is 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, or 29;

n is 15 and m is 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, or 31;


n is 16 and m is 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, or 33;






n is 17 and m is 11, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, or 35;

n is 18 and m is 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, or 37;

n is 19 and m is 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, or 39; or




n is 20 and m is 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 31, 33, 35, 37, 39, or 41.




5. A compound according to claim 3 wherein R is chosen from: H, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, n-butyl, 1-methylpropyl, 1-methyl-2-ethylbutyl, 2-ethylbutyl, 2-methylpropyl, tert-butyl, 2-methylcyclopropyl, 1-methylcyclopropyl, cyclobutyl, cyclopropylmethyl (i.e., ), n-pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 1-ethylpropyl, 1,2-dimethylpropyl, 1,1-dimethylpropyl, 2,2-dimethylpropyl,




cyclobutylmethyl (i.e., ), 2-(cyclopropyl)ethyl (i.e., ), cyclopentyl, n-hexyl, 1-methylpentyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 1,1-dimethylbutyl, 1,2-dimethylbutyl, 1,3-dimethylbutyl, 2,3-dimethylbutyl, 2,2-dimethylbutyl, 3,3-dimethylbutyl, 1,1,2-trimethylpropyl, 1,2,2-trimethylpropyl, 3-(cyclopropyl)propyl (i.e., ), 2-(cyclobutyl)ethyl (i.e., ), cyclopentylmethyl (i.e., ), cyclohexyl, cyclohexylmethyl, 2-cyclohexylethyl, dicyclohexylmethyl, n-octyl, benzyl, diphenylmethyl, decyl, dodecyl, tetradecyl, hexadecyl, hexadec-9-enyl, octadecyl, octadec-9-enyl, octadec-9,12-dienyl, 2-propylpentyl, 2-butylhexyl, 2-pentylheptyl, 2-hexyloctyl.



6. A compound according to claim 5 wherein R is chosen from: H, methyl, ethyl, n-propyl, isopropyl, n-butyl, tert-butyl, 2-methylbutyl, and 2-ethylbutyl.









7. A compound according to claim 2, with a structure selected from:

, , ,







, , ,

, , ,


, ,


,

,

,

,

,

,

, and

.


8. A compound according to claim 7, with a structure selected from:


,

,

,

,

, and

.


9. A compound according to claim 8, with a structure selected from




10. A compound according to claim 8, with a structure selected from



11. A compound according to claim 8, with a structure selected from



12. A compound according to claim 8, with a structure selected from



13. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound according to claim 1, or a pharmaceutically acceptable salt thereof.

14. A method of treating a seizure disorder, comprising administering to a subject a therapeutically or prophylactically effective amount of the compound of claim 1.

15. The method according to claim 14, wherein the seizure disorder is epilepsy.

16. The method according to claim 14, wherein the seizure disorder is status epilepticus.

17. The method according to claim 14, wherein the seizure disorder comprises partial-onset seizures or primary generalized tonic-clonic seizures, or any combination thereof.

18. The method according to claim 14, wherein the seizure disorder results from a heritable genetic seizure disorder.

19. The method according to claim 14, wherein the seizure disorder results from a brain tumor, a concussive brain injury, or a penetrating brain injury.

20. A method of treating pain, comprising administering to a subject a therapeutically or prophylactically effective amount of the compound of claim 1.